Public Sector Pension Investment Board Takes Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Public Sector Pension Investment Board purchased a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 150,820 shares of the life sciences company’s stock, valued at approximately $4,395,000. Public Sector Pension Investment Board owned 0.19% of Integra LifeSciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Capital Research Global Investors grew its position in shares of Integra LifeSciences by 37.7% during the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after buying an additional 1,621,655 shares in the last quarter. Madison Avenue Partners LP increased its position in Integra LifeSciences by 8.0% during the 4th quarter. Madison Avenue Partners LP now owns 1,042,156 shares of the life sciences company’s stock valued at $45,386,000 after purchasing an additional 77,489 shares during the period. Jane Street Group LLC raised its holdings in shares of Integra LifeSciences by 181.1% in the 1st quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company’s stock valued at $4,427,000 after purchasing an additional 80,463 shares in the last quarter. Leeward Investments LLC MA lifted its position in shares of Integra LifeSciences by 17.8% in the 1st quarter. Leeward Investments LLC MA now owns 452,438 shares of the life sciences company’s stock worth $16,039,000 after purchasing an additional 68,247 shares during the period. Finally, SG Americas Securities LLC increased its holdings in Integra LifeSciences by 606.9% during the second quarter. SG Americas Securities LLC now owns 67,471 shares of the life sciences company’s stock valued at $1,966,000 after buying an additional 57,927 shares during the period. Institutional investors own 84.78% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on IART. Citigroup lowered their target price on Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating for the company in a report on Thursday, August 22nd. BTIG Research decreased their price target on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating for the company in a research report on Wednesday, August 28th. Truist Financial cut their price objective on shares of Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a research report on Tuesday, July 30th. JMP Securities decreased their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Finally, Morgan Stanley lifted their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Four equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.63.

Integra LifeSciences Stock Up 1.9 %

NASDAQ:IART opened at $17.47 on Friday. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. Integra LifeSciences Holdings Co. has a twelve month low of $16.96 and a twelve month high of $45.42. The company has a market cap of $1.36 billion, a PE ratio of 34.94, a P/E/G ratio of 0.60 and a beta of 1.10. The company’s 50 day moving average is $21.60 and its two-hundred day moving average is $27.38.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. The firm had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.71 earnings per share. Analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.